Meeting NewsVideo

VIDEO: Therapeutic targets for spondyloarthropathies include IL-17, JAK

SAN DIEGO – One of the hottest topics at the American College of Rheumatology Annual Meeting was new data on therapeutic targets in the treatment of spondyloarthropathies, with many “interesting papers,” according to Beth L. Jonas, MD, FACR, professor of medicine and interim chief of the division of rheumatology, allergy and immunology in the Thurston Arthritis Research Center at UNC.

Specific targets include interleukin-17 and Janus kinase. The IL-17 inhibitors secukinumab and ixekizumab were highlighted, according to Jonas, as were the JAK inhibitors tofacitinib and baricitinib.

“I anticipate that there are other Janus kinase inhibitors that may have efficacy,” Jonas said. “We look forward to those studies in the future.”

SAN DIEGO – One of the hottest topics at the American College of Rheumatology Annual Meeting was new data on therapeutic targets in the treatment of spondyloarthropathies, with many “interesting papers,” according to Beth L. Jonas, MD, FACR, professor of medicine and interim chief of the division of rheumatology, allergy and immunology in the Thurston Arthritis Research Center at UNC.

Specific targets include interleukin-17 and Janus kinase. The IL-17 inhibitors secukinumab and ixekizumab were highlighted, according to Jonas, as were the JAK inhibitors tofacitinib and baricitinib.

“I anticipate that there are other Janus kinase inhibitors that may have efficacy,” Jonas said. “We look forward to those studies in the future.”

    See more from Discoveries from ACR: Spondyloarthropathies